ClinicalTrials.gg

Program

Elfetabart Drozuntecan

Also written as “BNT324” and “DB-1311”.

Its studies are mostly in Small Cell Lung Carcinoma · Prostatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Jan 23, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech22 open or runningphase 3since Jan 23, 2026Mar 19, 2025Sep 2028phase 2 · NCT06892548
DualityBio11 open or runningphase 2since Jun 13, 2023Jun 13, 2023Dec 2027phase 2 · NCT05914116

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2023First study: phase 2 study in Small Cell Lung CarcinomaNew to DualityBioDualityBio · NCT05914116 · 862 planned · United States, Australia, China and more
  2. Mar 19, 2025BioNTech’s first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06892548 · 594 planned · United States, Australia, China and more
  3. Jan 23, 2026Phase 3 study in Metastatic Castration-resistant Prostate CancerPhase 3 reachedBioNTech · NCT07365995 · 736 planned · United States, Australia, Belgium and more

Ahead

  1. Dec 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaDualityBio · NCT05914116
  2. Sep 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06892548
  3. Feb 2031Primary completion: phase 3 study in Metastatic Castration-resistant Prostate CancerBioNTech · NCT07365995

TargetBeta

CD276 →read by rule
“An antibody-drug conjugate (ADC) composed of elfetabart, a humanized monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), that is ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07365995Metastatic Castration-resistant Prostate Cancer · United States, Australia, Belgium and more3RecruitingBioNTechFeb 2031736
NCT06892548Small Cell Lung Carcinoma · United States, Australia, China and more2RecruitingBioNTechSep 2028594
NCT05914116Small Cell Lung Carcinoma · United States, Australia, China and more2RecruitingDualityBioDec 2027862

How it is read

Names in the registry

  • “BNT324”, 2 entries
  • “DB-1311”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.